News Image

Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2

Provided By GlobeNewswire

Last update: Sep 18, 2025

– On track for first FDA Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis –

Los Angeles, CA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that 50% enrollment milestone has already been surpassed in NEXICART-2, its relapsed/refractory AL Amyloidosis clinical trial of sterically-optimized CAR-T NXC-201. Immix continues to enroll expediently toward BLA submission.

Read more at globenewswire.com

IMMIX BIOPHARMA INC

NASDAQ:IMMX (10/24/2025, 8:00:02 PM)

After market: 3.64 +0.03 (+0.83%)

3.61

+0.18 (+5.25%)



Find more stocks in the Stock Screener

Follow ChartMill for more